论文部分内容阅读
本文对116例各种血液病人进行了铜蓝蛋白(CP)检测,了解其变化并探讨了其临床价值。 资料和方法 一、正常对照组:健康献血员30例(男20,女10),年龄25～58岁。 二、血液病组:116例(男84,女34),年龄17～70岁。其中白血病58例(ALL 16例,ANLL 38例,CML4例),多发性骨髓瘤(MM)8例,恶性淋巴瘤(ML)6例,再生障碍性贫血(AA)8例,特发性血小板减少性紫癜(1TP)10例,缺铁性贫血(1DA)15例,自身免疫性溶血性贫血(AIHA)3例,骨髓异常增生综合征(MDS)8例。 三、检测方法,采用放免分析法(RIA),试剂盒
In this paper, 116 cases of various blood patients were ceruloplasmin (CP) test to understand the changes and to explore its clinical value. Materials and Methods First, the normal control group: 30 healthy blood donors (male 20, female 10), aged 25 to 58 years. Second, blood disease group: 116 cases (male 84, female 34), aged 17 to 70 years. Including 58 leukemia patients (ALL 16, ANLL 38, CML 4), multiple myeloma (MM) 8, malignant lymphoma (ML) 6, aplastic anemia (AA) 8, idiopathic platelet 10 cases of purpura (1TP), 15 cases of iron deficiency anemia (IDA), 3 cases of autoimmune hemolytic anemia (AIHA) and 8 cases of myelodysplastic syndrome (MDS). Third, testing methods, radioimmunoassay (RIA), kits